Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 11.9% in the 1st quarter, HoldingsChannel reports. The fund owned 98,221 shares of the pharmaceutical company’s stock after acquiring an additional 10,425 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Vertex Pharmaceuticals were worth $47,664,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Quent Capital LLC raised its holdings in Vertex Pharmaceuticals by 4.5% in the 1st quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company’s stock valued at $249,000 after acquiring an additional 22 shares during the last quarter. Advisor OS LLC raised its holdings in Vertex Pharmaceuticals by 4.4% in the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after acquiring an additional 23 shares during the last quarter. Sculati Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 1.0% in the 4th quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company’s stock valued at $1,029,000 after acquiring an additional 25 shares during the last quarter. Avidian Wealth Enterprises LLC raised its holdings in Vertex Pharmaceuticals by 2.1% in the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock valued at $594,000 after acquiring an additional 25 shares during the last quarter. Finally, Strategic Blueprint LLC raised its holdings in Vertex Pharmaceuticals by 1.7% in the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock valued at $726,000 after acquiring an additional 25 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on VRTX. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Erste Group Bank downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, May 23rd. Wall Street Zen upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Royal Bank Of Canada dropped their price objective on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Finally, Guggenheim dropped their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Thirteen analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $497.10.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $389.88 on Tuesday. The business has a 50-day moving average of $443.83 and a 200-day moving average of $463.61. The company has a market capitalization of $99.96 billion, a PE ratio of 27.87 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same period in the prior year, the company posted ($12.83) EPS. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% on a year-over-year basis. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.